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Abstract
The breast cancer stem cell (BCSC) hypotheses suggest that breast cancer is derived from a single
tumor-initiating cell with stem-like properties, but the source of these cells is unclear. We previously
observed that induction of an immune response against an epithelial breast cancer led in vivo to the
T cell-dependent outgrowth of a tumor, the cells of which had undergone epithelial to mesenchymal
transition (EMT). The resulting mesenchymal tumor cells had a CD24−/loCD44+ phenotype,
consistent with BCSCs. In the present study, we found that EMT was induced by CD8 T cells and
the resulting tumors had characteristics of BCSCs, including potent tumorigenicity, ability to re-
establish an epithelial tumor, and enhanced resistance to drugs and radiation. In contrast to the
hierarchal cancer stem cell hypothesis which suggests that breast cancer arises from the
transformation of a resident tissue stem cell, our results show that EMT can produce the BCSC
phenotype. These findings have several important implications related to disease progression and
relapse.
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Introduction
A current goal among breast cancer scientists worldwide is to reduce the risk of breast cancer
recurrence following therapy (1). This risk, which remains high for at least one decade, suggests
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that treated patients still maintain a small population of tumorigenic, albeit dormant, cancer
stem cells. Although previously described (2), it was not until 2003 that interest in breast cancer
stem cells (BCSCs) was renewed (3). In that study, identification of the CD24−/loCD44+
tumorigenic breast cancer cells provided a valuable marker framework for testing hypotheses
on BCSC involvement in the clinical course of breast cancer and its pathogenesis.
A prevalent BCSC hypothesis proposes that breast tumors are initiated and maintained by a
small fraction of tumorigenic cells (4). What remains unclear about the BCSC hypothesis is
the origin of the tumorigenic cells. One hypothesis is that transformed resident tissue stem cells
undergo asymmetrical division, occasionally renewing a copy of themselves but most often
generating proliferative epithelial daughter progeny with limited tumorigenicity. An alternative
hypothesis is that BCSCs are derived from transformed, differentiated epithelial cells by
acquisition of stem cell attributes. Determining the origin and biology of BCSCs is important
for the development of therapies to reduce the risk of breast cancer relapse.
In prior work, we found that immunoediting of breast tumors in the neu-transgenic (neu-tg)
mouse resulted in neu antigen-loss variant tumors (5–8). Our first observation was that the
variants had a different proteomic profile and reduced inflammatory and danger signals (7).
Subsequent analyses revealed that antigen-loss tumor cells had undergone T cell-dependent
epithelial to mesenchymal transition (EMT) (5,6). EMT, a de-differentiation program that
converts epithelial cells into a mesenchymal phenotype, is involved in embryogenesis and used
pathologically during cancer progression (9). Since our studies showed that mesenchymal
antigen-loss variants were CD24−/lo, we assessed whether these antigen-loss tumor cells had
characteristics of CD24−/lo BCSCs observed by Al-Hajj et al. (3,6). Furthermore, we aimed to
determine what T cell subset was involved in the induction of EMT. Herein, we show that EMT
induction in vivo involves CD8 T cells and generates BCSCs.
Materials and Methods
Animals
Female neu-transgenic (neu-tg) mice on the FVB background and FVB/N mice were
maintained as a colony in accordance with institutional policy.
Cell lines
The epithelial cell line (E), was derived as previously described (10). Four cell lines (M1, M2,
M3 and M4) were obtained from relapsed tumors that underwent EMT following injection of
E tumor cells into parental non-transgenic FVB/N mice (6). All cell lines were maintained in
RPMI 1640 containing 10% fetal bovine serum (FBS), 1% penicillin/streptomycin, 1% sodium
pyruvate, 2.5% HEPES and 2mM L-glutamine.
In vivo tumorigenicity assays
Neu-tg mice were inoculated, subcutaneously on the mid-dorsum unless otherwise specified,
with doses of tumors cells ranging from 100 to 106 cells. Tumors were measured every other
day with vernier calipers and volumes were calculated as the product of length × width × height
× 0.5236.
Antibodies for in vivo cell depletion
Anti-CD4 (GK1.5) and anti-CD8 (53.6.72) monoclonal antibodies were prepared by the Mayo
Antibody Core Facility (Rochester, MN). Mice were injected daily for 5 days with 100μg of
antibody intravenously and E tumor cells were injected 48 hours later. For secondary depletion
of CD8s, mice previously injected with E tumor cells received 5 more daily doses of anti-CD8
and were rechallenged with tumors.
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Proliferation of M3 cells in response to CD8 T cell conditioned media
CD8 T cells were derived from lymph nodes and spleens of naïve FVB mice with a mouse
CD8a+ T cell isolation kit per manufacturer’s recommendations using an autoMACS Separator
(Miltenyi Biotec Inc Auburn, CA). Two million/well untouched CD8+ T cells were plated in
6 well plates. Unstimulated wells contained CD8s and media. CD8s were treated with 2 million
irradiated splenocytes (3300 rads) and 250 μg of concanavalin A (ConA). Anti-CD3/CD28
received 400,000 mouse Dynabeads (Invitrogen, Carlsbad, CA) per well (~1 bead/5 T cells).
100 μl of 18 hour conditioned media were added to M cells previously seeded into 96-well
plates. 3H thymidine was added, 0.273 nCi per well; 24 hours later cells were harvested and
read on a TopCount NXT scintillation counter (Perkin Elmer, Waltham, MA).
Flow cytometry
Cells were incubated with primary antibodies at 4°C for 20–30 minutes, washed, followed by
secondary antibody (if needed) for 20 minutes, washed and fixed with 0.5% formaldehyde.
Samples were run on BD FACScan or FACSCalibur flow cytometers (BD Bioscience, San
Jose, CA). Sorting of M3 cells was performed on a BD FACSVantage Cell Sorter and data
was analyzed using BD CellQuest Pro software (ver. 4.0.2). Occasionally, results depicted the
relative mean fluorescent intensity (rMFI) (ratio of specific marker intensity to the isotype or
secondary antibody staining).
Flow cytometry reagents
Antibodies and reagents from BD Pharmigen (San Diego, CA) included anti-CD24 FITC
(M1/9), anti-CD44 FITC, PE-Cy5 (IM7), anti-Sca1 FITC (D7), anti-Annexin V APC and 7-
AAD. Antibodies from eBioscience (San Diego, CA) were anti-CD24 PE (30-F1), anti-CD34
FITC (RAM34), anti-CD133/Prominin I FITC (13A4). Rabbit anti-claudin 3 (Z23.JM) was
from Zymed/Invitrogen. The mouse monoclonal antibody against rat neu (7.16.4) was
previously described (6). Secondary antibodies from Jackson ImmunoResearch Laboratories
(West Grove, PA) were FITC goat anti-rabbit IgG and FITC anti-mouse IgG. Anti-mouse
IgG2a/2b FITC (R2–40) was from BD Pharmigen. Isotype antibodies were PE Rat IgG2b
(eBioscience), FITC Rat IgG2b (BD Pharmingen) and Pe-Cy5 Rat IgG2b (195-1, BD
Pharmingen). BD Cytofix/Cytoperm Fixation/Permeabilization solution kit (BD Pharmingen)
was used for Claudin 3 staining.
In vitro coculture of E cells with primed CD8s
FVB mice were injected with 5 million E tumor cells and spleens removed 7 days later to isolate
primed CD8 T cells as described above. In 6 well plates, 2.5 × 105 E cells and 2 × 106 CD8 T
cells were added per well. CD8 T cells were irradiated to 3300 rads. Cells were co-cultured
for 24 hours, T cells washed off, and tumor cells stained for neu and CD24 and analyzed by
flow cytometry.
PCR analysis
RNA was isolated using RNeasy (Qiagen, Valencia, CA). PCR primers, selected with
MacVector software (MacVector, Inc., Cary, NC) were from Invitrogen. RT-PCR utilized
SuperScript One-Step RT-PCR with Platinum Taq (Invitrogen) using 100 or 200 ng of RNA
in a Bio-Rad MyCycler. Samples were electrophoresed on 1% agarose gels, imaged on a Gel
Doc XR (Bio-Rad, Hercules, CA), and band intensities quantified with Quantity One software
(ver. 4.5.2). DNA repair gene expression analysis was done using DNA Damage Signaling
RT2 Profiler PCR Array qPCR kit (SuperArray Bioscience, Frederick, MD) according to the
manufacturer’s protocol and run on a Mx3005P thermal cycler (Stratagene, La Jolla, CA).
Expression was normalized to housekeeping genes and expressed as fold relative to the E cell
line.
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Cell Photography
40X images of cell lines were taken using an Axiovert 200M inverted microscope and
AxioCam HRm camera interfaced with Axiovision software (Carl Zeiss, Thornwood, NY).
20X images of spheroids were obtained with a Leica DC 200 microscope (Leica Microsystems,
Wetzlar, Germany) and Fujifilm FinePix 6800 Zoom camera (Fujifilm, Tokyo, Japan).
Histology
M3 and E tumors from neu-tg mice were frozen in O.C.T. Compound (Tissue-Tek, Sakura
Finetek USA, Torrance, CA), cryo sectioned and stained with hematoxylin and eosin. 20X
images were gathered using a NanoZoomer Digital Pathology (Bacus Laboratories, Inc.) slide
scanner and captured using WebSlide Enterprise software. Staining and imaging of frozen
tumor sections was performed by the Tissue and Cell Molecular Analysis of the Mayo Clinic
Cancer Center using standard techniques.
Western blotting
Protein was isolated from whole cell lysates using cell extraction buffer (Invitrogen) and
concentration determined using the BCA assay (Pierce/Thermo Fisher Scientific Inc.,
Rockford, IL). Eighty to 150 μg of protein was subjected to SDS-PAGE electrophoresis and
transferred to PVDF membranes which were blocked for 1 hour with skim milk (3% w/v of
PBS with Tween 20: PBS-T) and incubated overnight (4°C) with monoclonal antibodies
against BCRP (BXP-21) or PGP (C219) from Calbiochem (Gibbstown, NJ) diluted 1:50 and
1:500, respectively. Membranes were washed and incubated with alkaline phosphatase-
conjugated anti-mouse IgG (Chemicon/Millipore, Billerica, MA) for 1 hour (1:8000 dilution)
followed by detection with enhanced chemiluminescence (GE Healthcare). Anti-β-actin was
employed as loading control (AC-74, Sigma Aldrich, St. Louis, MO).
Chemotherapy assays
Mitoxantrone dihydrochloride was from Sigma Aldrich, BCNU from the Chemical Synthesis
Branch, NCI (Bethesda, MD), and Etoposide from Biomol International (Plymouth Meeting,
PA). MTT cellular proliferation assays were employed (11) for mitoxantrone chemosensitivity.
5000 E and M cells were plated in 96-well plates in complete medium overnight and thereafter
in serum free medium. Cell lines were exposed to increasing concentrations (0, 2.5, 5, 10 and
20 μM) of mitoxantrone (diluted in 95% ethanol) for 72 hours. Media was aspirated from wells
and 15 μL/well MTT reagent (3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide,
Sigma Aldrich) was added and incubated for 4 h at 37°C followed by 100 μL of stop solution.
The following day plate optical densities were measured at 562 nm in an ELISA SpectraMax
190 reader (Molecular Devices, Sunnyvale, California). Percent inhibition of growth was
measured as a percent of control (no mitoxantrone). For apoptotic assays, cells were plated and
treated with 2 μM etoposide for 24 hours followed by staining with Annexin V and 7-AAD.
The percentage of apoptotic cells was determined by flow cytometry as described (12).
Clonogenic assays
500 cells were plated in P35 dishes and treated 24 hours later with irradiation or BCNU.
Irradiation was performed with a 137Cs laboratory irradiator to generate a dose curve of 0, 4,
8, 16 and 32 Gy or cells were exposed to increasing doses (0, 2.5, 5, 10 and 20 μM) of BCNU.
After 8 days, cells were washed, stained with crystal violet, and colonies counted.
MMP activity assay
The EnzoLyte 520 Generic MMP Fluorometric Assay Kit (AnaSpec, San Jose, CA) was used
according to manufacturer’s directions. Cell culture supernatants were incubated with 1mM
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APMA for 24 hours at 37°C to activate pro-MMPs. Fluorescence was measured at 490/520nm
Ex/Em using a Victor V plate reader (Perkin Elmer, Waltham, MA).
RNA microarray
Affymetrix microarray analysis was done by the Mayo Advanced Genomic Technology Center
(Rochester, MN) as previously described (6) using GeneChip Mouse Genome 430 2.0 arrays.
The expression analysis was performed with Affymetrix Genechip Operating Software with a
scaling target signal of 500 and normalization of 1. Microarray data is posted on Gene
Expression Omnibus as GSE13259.
Spheroids
Cells from monolayer cultures were harvested and resuspended at a density of 4 × 104 viable
cells per milliliter in serum-free MEBM (Cambrex Bioscience Walkersville Inc, MD)
supplemented with 2% B27 (Invitrogen), 20ng/mL EGF (BD Biosciences), 100 μL
mercaptoethanol, 4μg/mL insulin (Sigma), 1 ng/mL hydrocortisone, 1% penicillin/
streptomycin, 0.25 μg/mL amphotericin B, 20 μg/mL gentamicin sulfate and seeded into 10
cm dishes coated with 1% agarose. Cultures were fed weekly.
Statistical analyses
Statistical analysis was performed using Prism 4 for Windows (version 4.03, GraphPad
Software, San Diego, CA). Data were analyzed using one-way ANOVA when comparing E
with each of the M cell lines with the Bonferroni multiple comparison test (Kruskal-Wallis as
non-parametric) or one-tailed Student’s t-tests. Statistical significance was set at p≤0.05. The
number of replicates is indicated with each figure.
Results
Induction of EMT in vivo requires CD8 T cells
Immune rejection of neu+ epithelial (E) breast tumors in the FVB/N mouse, where neu is a
foreign antigen, results in T cell- and IFN-γ-dependent induction of neu antigen-loss (neu−)
variant tumors that have undergone EMT (5,6). To determine which T cell subset was
responsible, we depleted CD4 or CD8 T cells from FVB/N mice prior to challenge with
neu+ E tumor cells. Control mice developed tumors around 40 days while those depleted of
CD4 T cells developed tumors around 20 days (Figure 1A) (6). Consistent with prior work,
control mice developed neu− variants while those depleted of CD4 T cells had neu+ tumors
(not shown). Mice depleted of CD8 T cells, however, remained disease-free (Figure 1A). Long-
term observation (>100 days) suggested complete tumor rejection (not shown). Four possible
reasons could explain why tumors did not grow in CD8 T cell-depleted mice. The first is that
CD8 T cell depletion permitted a more robust immune response against neu− EMT variants.
To test this, CD8 T cell-depleted mice that rejected tumor were rechallenged with neu− EMT
variants. If robust immunity against neu− EMT variants existed, these mice should reject tumor,
which we did not observe (Figure 1B). The second possible reason is that CD8 T cells
preferentially support enhanced growth of the neu− EMT variants contained as a small
population within the E cell line. To test this, conditioned culture medium from CD8 T cells
was applied to neu− EMT variants in vitro. Neu− EMT variant tumor cells exposed to
conditioned medium did not grow any better than those incubated with control medium
(p>0.05), ruling out the likelihood that growth of these cells was enhanced by growth factors
derived from CD8 T cells (Figure 1C). A third possibility is that CD8 T cells promote the
malignant transformation of stromal cells that associate with the nascent tumor. This is ruled
out because these mesenchymal tumors contain the neu oncogene, which is not in the FVB/N
genome (5). The only remaining possibility is that CD8 T cells directly induce neu− EMT
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variants. These findings, along with prior work, demonstrate that the generation of neu− EMT
variants in the FVB/N mice is an active rather than a selective process (5). To further support
this, we found that E cells cultured with tumor-primed CD8 T cells lost neu and CD24
expression (p=0.0009) (Figure 1D). This was partially ablated by prior irradiation of the CD8
T cells, which is known to blunt T cell proliferation and cytokine production. Naïve CD8 T
cells failed to generate antigen-negative tumor cells (not shown).
Stable mesenchymal cell lines were established
Four neu− EMT variant cell lines (M1, M2, M3, and M4) were established from 4 different
tumors. All were neu− as assessed by RT-PCR (not shown). Consistent with having undergone
EMT, the M cell lines had significantly reduced levels of the epithelial markers E-cadherin
and claudin 3 (p=0.0001) (Figure 2A). Moreover, mesenchymal markers N-cadherin and Snail
were upregulated in M cell lines (Figure 2B). Increased mesenchymal function, as measured
by matrix metalloproteinase (MMP) activity, was increased significantly (p<0.01) in all lines,
except M1 relative to the parental E cell line (Figure 2B). Visual inspection (Figure 2C) showed
that M cell lines had a scattered, spindle-shaped appearance while the E cell line had strong
cellular junctions with a cobblestone appearance. FISH karyotyping revealed that each M cell
line contained, like the parental E cells, a single integration site for rat neu within chromosome
3 (Supplementary Figure 1).
Mesenchymal cells are CD24−/loCD44+ and highly tumorigenic
Human BCSCs have been distinguished from non-tumorigenic cells by the cell surface marker
profile CD24−/loCD44+ (3). Since our prior work showed that CD24 was down-regulated in
neu− EMT variant tumors, we hypothesized that M cells may have a BCSC profile. As shown
in Figure 3A, the M cell lines were largely CD24−/lo and CD44+ in contrast to the
CD24+CD44+ E cells. CD24 expression was significantly lower in all M cells relative to the
E cells (p=0.004). CD34, a sialomucin expressed on mesenchymal stem cells (13), was not
significantly elevated (p=0.63) in M cell lines relative to E cells (Supplementary Figure 2).
Consistent with prior work, the M cells had low and intermediate expression of stem cell
antigen-1 (Sca-1), although elevated relative to E cells it was not statistically significant
(p=0.23) (Supplementary Figure 2). CD133, a marker of hematopoietic stem cells, was also
examined given its association with human cancer stem cells (CSCs) (14). Staining revealed
similarly low expression in both tumor types (p=0.74) (Supplementary Figure 2).
A key property of CSCs is their ability to seed tumors at very low numbers. In vivo studies
showed that M tumor cells were far more tumorigenic than E cells (Figure 3B, Table). M cells
formed tumors in 100% of mice at doses of ≥1000 cells, and M3 formed tumors with as few
as 100 cells. E cells only formed tumors when 106 cells were injected (Figure 3B, Table).
Despite large differences in tumorigenicity, both cell types were able to form spheroids in
vitro under conditions that prevented attachment (Supplementary Figure 3). However, the M
cells generated spheroids with greater efficiency than E cells (p<0.0001)(Figure 3B).
Mesenchymal tumor cells generate neu+CD24hiCD44+ tumors in neu-tg mice
Another unique feature of BCSCs is an ability to give rise to epithelial progeny that constitute
the bulk of a tumor. To examine whether the mesenchymal cells could reconstitute an epithelial
tumor, M tumor cells were injected into the neu-tg mouse, which carries the neu transgene and
will not reject neu+ tumors. Since some M cells showed a minor population with moderate
CD24 expression, we sorted CD24− tumor cells from CD24lo/int tumor cells. Both fractions
formed tumors upon injection of 105, 104 or 103 cells with nearly equal efficacy (not shown).
M cells were able to reconstitute tumors that regained CD24 expression and maintained high
CD44 expression levels (Figure 3C). Histologic analysis of tumors from E and M3 cells show
no remarkable differences (Supplementary Figure 4). However, neu expression was poorly
Santisteban et al. Page 6
Cancer Res. Author manuscript; available in PMC 2010 April 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
upregulated, a finding consistent with our prior study showing that the neu-transgene MMTV
promoter in the neu− EMT variant tumors is heavily methylated (5). Indeed, neu expression
could be regained by injection of M tumor cells into the mammary fat pad, a site of preferential
activation of the MMTV promoter. In fact, M1 cells regained complete neu expression in the
mammary fat pad but not in the flank (p= 0.002) (Figures 3C). CD24 and neu expression were
also induced, albeit moderately, in M1 cells grown under spheroid forming conditions
(Supplementary Figure 5).
Mesenchymal cell lines have elevated expression of drug pumps and DNA repair enzymes
and are resistant to cytotoxic agents
Another hallmark of BCSCs is their ability to resist environmental insults. Both mesenchymal
cells and BCSCs have been linked to resistance to drugs and radiation in recent studies (15).
Cytotoxic resistance is often due to elevated expression of drug pumps. Two pumps associated
with resistance in breast cancer are BCRP and PGP (16). We observed higher expression of
both pumps in mesenchymal cells relative to parental cells (Figure 4A). Enhanced
chemoresistance of M cells to mitoxantrone or etoposide (substrates for BCRP and PGP,
respectively) suggests that these pumps are active (Figure 4A).
Our mesenchymal tumor cells also have elevated expression of key DNA repair enzymes. One
enzyme involved in drug resistance in human cancers is O6-methylguanine-DNA
methyltransferase (MGMT), a ubiquitous DNA repair protein that removes O6-alkyl-guanine
lesions from damaged DNA and contributes to the resistance of brain cancers to α-chloro-
nitrosourea (BCNU) (17). Figure 4B shows that M cells have high expression of MGMT (>200
fold higher relative to E cells) and are resistant to BCNU treatment (p=0.0002 at 20μM). Since
human BCSCs are resistant to ionizing radiation (18), we evaluated this and expression of
double-stranded DNA repair pathway components (i.e. Brca2, H2afx, Mre11a, Prkdc,
Rad52, and Xrcc6). Relative to E cells, M tumor cell lines showed elevated expression of
H2afx and Xrcc6 (Figure 4C). Activation of H2afx enhances DNA repair efficiency (19) and
the KU-70 protein (encoded by Xrcc6) has a key role by recruiting the DNA-dependent protein
kinase (20). In general, levels of double-stranded DNA repair genes were similar to E cells,
except Prkdc, the gene encoding the catalytic subunit of the DNA-dependent protein kinase
(DNA-PK), whose expression was reduced in two M cell lines. Nonetheless, this altered
expression of the double-stranded DNA repair pathway was associated with strong resistance
of M cells to γ-irradiation (p=0.003 at 16Gy) (Figure 4C). Additional irradiation experiments
demonstrated E cells were more sensitive to irradiation as compared to M cells, when assessed
by apoptosis assays (not shown).
Gene expression of luminal or basal epithelial markers in mesenchymal cells suggests that
EMT is incomplete
The normal mammary epithelium contains two layers, basal and luminal. These layers are
distinguished by unique cytokeratins (Cks) (21). Ck5 and Ck14 are expressed by the basal layer
and Ck8 and Ck18 by the luminal layer (21,22). Since Ck expression is confined to epithelial
cells, we investigated whether EMT was complete based on loss of Ck expression in our cell
lines. E tumor cells have the characteristic signature of high Ck8 and low Ck14 expression
consistent with their luminal differentiation (Figure 5A). There was no consistent pattern of
modulation of Cks observed in the mesenchymal cells. While the M1 cell line showed loss of
Ck8 and maintained low level Ck14 expression, M2, M3, and M4 cell lines maintained Ck8
and increased Ck14 expression. Other frequently cited markers of luminal (EpCAM, MUC1,
galectin 3, claudin 4 and Ck18) and basal (CD10, osteonectin, S100, myosin light chain and
integrin alpha 6) epithelial phenotypes were also assessed (Figures 5B–C). Of the luminal
markers, EpCAM (p<0.0001) and claudin 4 (p<0.0001) were consistently downregulated in
all M lines relative to the E lines and MUC1 was not expressed by any line. Like Ck8, Ck18
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expression was inconsistent. Of the basal markers, only osteonectin was convincingly elevated
(p<0.0001), an expected finding given its expression in mesenchymal stem cells (23) (Figure
5C). The other basal markers did not change and failed to distinguish E from M tumor cells.
Collectively, the results show that EMT is incomplete.
Discussion
While great strides in breast cancer treatment have been made, women treated for the disease
remain at high risk for recurrence. Recent hypotheses suggest that recurrence (and possibly
tumor initiation) is caused by a subset of tumor cells with stem cell qualities including self
renewal, ability to differentiate and reconstitute a tumor, and resistance to chemotherapeutic
drugs and radiation. While studies have confirmed the existence of this tumorigenic subset,
their origin is unclear. Understanding the origin and biology of these cells may reveal strategies
for targeting them therapeutically. In this study, we made three novel observations which
provide an additional framework for BCSCs. These observations are that (1) EMT was induced
in vivo by CD8 T cells, (2) EMT generates mesenchymal tumor cells with BCSC properties,
and (3) EMT (and BCSC genesis) is not associated with complete loss of epithelial
characteristics.
Although much evidence demonstrates the importance of EMT in embryogenesis, investigation
of its role in cancer has been confined mainly to in vitro model systems. As a result, the
relevance of natural EMT to in vivo malignancy is controversial. In the current study, we found
that EMT was induced in vivo without prior manipulation of tumor cells. Our conclusion that
the tumor cells had undergone EMT was based on a number of molecular and cellular changes
including (1) loss of the epithelial markers CD24, E-cadherin, and claudin 3, (2) gain of
validated mesenchymal markers N-cadherin and Snail, (3) gain of matrix metalloproteinase
activity, and (4) acquisition of a scattered phenotype. Prior studies showed that mesenchymal
tumors develop in the neu-tg mouse, but it remained unclear whether the appearance of the
mesenchymal tumors was due to selection or induction (5,6,24). Our findings clarify this by
showing CD8 T cell-dependent EMT induction in vivo.
Various immune effector cells are known to produce factors capable of inducing EMT, such
as TGF-β and TNF-α (25,26). Of those, the notable example is TGF-β. While CD4 T regulatory
cells are the predominant source of TGF-β among T cells, newer studies show that chronically-
stimulated effector CD8 T cells can also become regulatory and produce TGF-β (27). Another
potential mediator is the recently discovered product of the FAM3C gene, interleukin-like EMT
inducer (ILEI). Although little is known of ILEI, it appears to be highly expressed in
lymphocytes associated with chronic inflammatory lesions (e.g. arthritis and tumors) (24).
Bates and colleagues observed that TGF-β and TNF-α synergistically induced EMT in human
colon cancer cells (25). The requirement of multiple stimuli for EMT is supported by our prior
studies showing that engagement of the IFN-γ receptor is necessary for the generation of
antigen-loss variants in vivo, but IFN-γ stimulation in vitro leads only to a modest loss of neu
antigen (5). Whatever mechanism is operative, the induction of EMT and the generation of the
BCSC phenotype were observed in vivo, suggesting that our results may be biologically
relevant events. Our findings in mice are also consistent with prior studies which showed that
CD8 T cell infiltration is associated with lymph node metastasis in breast cancer patients
(28).
EMT was accompanied by the acquisition of BCSCs’ properties, including tumorigenicity,
resistance to environmental insults, ability to re-differentiate into an epithelial tumor, and
ability to form spheroids. These findings are consistent with those of Mani and colleagues who
recently showed that forced expression of EMT-associated molecules such as Snail and Twist
or treatment with TGF-β resulted in cells with a CSC phenotype (29). Similarly, Morel et al.
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with the same cell lines demonstrated that adding active Ras generated a population of
CD24−CD44+ cells that underwent EMT and had BCSC attributes (30). One key characteristic
of CSCs called into question by our studies is the need for self renewal, a property that ensures
preservation of CSCs in the tumor. Our hypothesis offers an alternative to self renewal,
suggesting that a tumor cell with cancer stem cell properties could be generated from
differentiated epithelial tumor cells through the aberrant use of EMT. This premise of de-
differentiation is supported by the recently described generation of pluripotent stem cells from
seemingly terminally-differentiated somatic cells (31,32). Inducing a CSC from differentiated
daughter cells could likely explain the shortcomings of the hierarchal self-renewing BCSC
hypothesis. That hypothesis does not easily explain why relapse is closely associated with
metastasis and invasion, features not readily linked to normal mammary stem cells (33,34).
Based on the current study and hallmarks of these prior studies, a likely alternative explanation
for relapse and disease progression is that a few of the tumor cells within the primary tumor
separate from the primary lesion using EMT and are not eliminated by conventional therapies,
due in part to physical separation but primarily to the inherent drug and radio resistance of the
mesenchymal tumor cells. Such a hypothesis is supported by Moody et al. which showed that
the EMT inducer Snail is linked to relapse in human breast cancer (24). EMT might also explain
why relapse in breast cancer is linked with a wound response signature (35). Mesenchymal
tumor cells may have several characteristics in common with normal healthy mesenchymal
stem cells, which have roles in the wound repair and healing response (36).
Stemness has been associated with the CD24+ phenotype in murine mammary models
including CD24+CD29hi (37) and CD24+Sca1− (21). In contrast to these data, we have found
stemness associated with the CD24−/lo cells. Although not directly addressed by our study,
there are at least two possibilities to explain these discrepancies. First there may be multiple
types of cells, generated during malignant transformation and progression that have BCSC-
like properties. Secondly, markers used to identify BCSC traits may be variable and reflect the
context or microenvironment from which the cells were derived as has been described by
Bissell and others (38).
Although our results demonstrate that the tumor cells underwent EMT, as assessed using well-
established markers, gene transcription analysis suggests that EMT was incomplete because
luminal and basal epithelial associated genes remained expressed. These results are consistent
with observations that EMT is associated with some but not all genetic changes ordinarily
associated with the stromal or mesenchymal phenotype (39). In other words, EMT may be
incomplete or aberrant. Our results are also consistent with a recent study in human breast
cancer that revealed that a small fraction (<10%) of the disseminated Ck expressing tumor cells
demonstrate the CD24−/loCD44+ BCSC phenotype (40). The implications of our findings could
be important for identifying evidence of EMT in breast cancer lesions with strict marker
paradigms that include the absence of Cks and E-cadherin expression.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Induction of EMT in vivo requires CD8 T cells
Panel A shows tumor growth in control, CD4-depleted, and CD8-depleted mice. Each point
is the mean (s.e.m.) of measurements from 3 tumors. A repeat experiment yielded identical
results. Panel B, tumor growth (mean and s.e.m., n=3) in CD8-depleted mice that had been
injected with parental E cells on day 0 and rechallenged at day 47 with antigen-loss variant
tumor cells (M3). Panel C, shown are the proliferation rates (counts per minutes incorporation
of thymidine) of antigen-negative tumor cells incubated with RPMI-1640 + 10% FBS (control
medium), medium with 20% FBS, conditioned medium from resting CD8 T cells (resting CD8
CM), conditioned medium from anti-CD3/anti-CD28 stimulated T cells, or conditioned
medium from ConA-stimulated T cells cocultured with irradiated splenocytes. Each bar is the
Santisteban et al. Page 12
Cancer Res. Author manuscript; available in PMC 2010 April 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
mean (s.e.m., n=3). Panel D, shown are the percentages of tumor cells which lost neu and had
reduced CD24 (epithelial marker) expression following exposure of epithelial (E) tumor cells
to control (regular) medium, tumor-primed CD8 T cells (PCD8), or irradiated tumor-primed
CD8 T cells (irPCD8). Each bar is the mean (s.e.m.) of 3 separate samples.
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Figure 2. Stable cell lines from tumor cells that underwent EMT were established
Panel A shows expression levels of E-cadherin and claudin 3 in E and M cell lines. The E-
cadherin experiments were repeated independently 3 times with similar results. Claudin 3 was
measured using flow cytometry and each bar is the mean (s.e.m.) of 2 separate experiments.
Panel B shows expression of N-cadherin, and Snail, and matrix metalloproteinase (MMP)
activity for all cell lines. The bars represent the signal intensity derived using RT-PCR. RT-
PCR results are representative of 2 experiments that gave nearly identical results. For MMP
activity each bar is the mean (s.e.m.) of 3 samples. Panel C shows light microscope pictures
(40X) of the cell lines. Bar=100 μm.
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Figure 3. Mesenchymal cells are CD24−/loCD44+ and highly tumorigenic
Panel A shows a representative histogram demonstrating that mesenchymal (M) tumor cells
are CD24−/lo CD44+. Dark and light tracings represent specific and isotype fluorescence,
respectively. Panel A also shows graphs that summarize CD24 and CD44 expression in the E
and M cells. Shown are the average (± s.e.m.) relative mean fluorescent intensities (rMFI)
calculated from 3 experiments. Panel B shows tumor growth curves of the E (left) and M3
(right) cell lines injected into neu-tg mice. Each data point is the mean (s.e.m.) tumor size
calculated from three mice. Numbers indicate the dose of cells injected. On the right, images
of the tumors (20X) and spheroids (20X) corresponding to E and M3 cell lines. The far right
graph shows the mean (± s.e.m, n=5 independent experiments) spheroid forming efficiency of
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each line. Panel C (left) is a summary of dot plots from CD24, CD44, and neu expression in
tumors derived from sorted CD24−CD44+ M3 mesenchymal cells. This experiment is
representative of 4 similar experiments done with each of the mesenchymal cells lines.
Quadrants were established using M3 cell line cells (not shown). Inset numbers indicate
percentage of gated cells in upper right quadrant. Panel D shows histograms of neu expression
in cells from a mesenchymal cell line (Line), flank tumors (Flank), and mammary fat pad
tumors (Fat pad) are shown. Inset numbers represent the relative mean fluorescent intensity.
Nearly identical results were seen with 4 different samples of each cell type which is shown
averaged in accompanying graph.
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Figure 4. Mesenchymal cell lines have elevated expression of drug pumps, DNA repair enzymes
and are resistant to environmental insults
Panel A (left) shows western blot analysis of BCRP and PGP drug pumps in all cell lines. β
actin was used as a loading control. Western blots are representative of three experiments for
each protein. Panel A (middle) shows inhibition of growth (i.e. compared to control treated
cells) of the tumor cells lines after in vitro treatment with mitoxantrone. Panel A (right) shows
the apoptotic response to etoposide as assessed using flow cytometry. Each bar is expressed
as the % apoptotic cells following treatment. A representative experiment is shown for MTT
and apoptotic assays, both performed twice. Panel B (left) depicts the expression levels of
MGMT in the tumor cell lines by real time PCR. Results are expressed as fold expression over
E and represent one experiment. Panel B (right) shows the results of a clonogenic assay of
the tumor cells following exposure to escalating doses of BCNU. Each data point is the mean
(s.e.m.) of 3 replicates. Panel C (left) shows the results of real-time PCR analysis of the double
stranded DNA repair genes. Results are expressed as fold expression over E. Panel C
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(right) shows the results of clonogenic assay after escalating doses of gamma irradiation. Each
data point is the mean (± s.e.m.) of 3 replicate plates.
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Figure 5. Gene expression of luminal or basal epithelial markers in mesenchymal cells suggests that
EMT is incomplete
Panel A shows the RT-PCR results depicting expression of CK8 (left) and CK14 (right) in
the tumor cell lines. Results are representative of 3 independent experiments. Panels B and
C show RNA microarray analyses of common luminal epithelial and basal markers in the cell
lines, respectively. Shown are the mean (s.e.m.) signal intensities of 2 microarray analyses for
each cell line. Each bar represents the signal intensity for a unique probe.
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